S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44

Applied Genetic Technologies (AGTC) Stock Forecast, Price & News

+0.02 (+2.75%)
(As of 05/16/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
210,021 shs
Average Volume
483,297 shs
Market Capitalization
$32.10 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

Applied Genetic Technologies logo

About Applied Genetic Technologies

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.


AGTC to Participate in Upcoming Investor Conferences
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$500 thousand
Book Value
$2.01 per share


Net Income
$-57.83 million
Pretax Margin




Free Float
Market Cap
$32.10 million

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

2.12 out of 5 stars

Medical Sector

460th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

76th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

Is Applied Genetic Technologies a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Applied Genetic Technologies stock.
View analyst ratings for Applied Genetic Technologies
or view top-rated stocks.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) announced its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same period in the prior year, the company earned ($0.60) earnings per share.
View Applied Genetic Technologies' earnings history

What price target have analysts set for AGTC?

6 Wall Street analysts have issued 1-year target prices for Applied Genetic Technologies' shares. Their forecasts range from $10.00 to $24.00. On average, they anticipate Applied Genetic Technologies' share price to reach $15.00 in the next year. This suggests a possible upside of 1,905.6% from the stock's current price.
View analysts' price targets for Applied Genetic Technologies
or view top-rated stocks among Wall Street analysts.

Who are Applied Genetic Technologies' key executives?
Applied Genetic Technologies' management team includes the following people:
  • Ms. Susan B. Washer, Pres, CEO & Director (Age 61, Pay $788.55k) (LinkedIn Profile)
  • Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 66, Pay $492.17k)
  • Dr. Nicholas Muzyczka, Co-Founder
  • Dr. Barry J. Byrne M.D., Ph.D., Co-Founder
  • Dr. William W. Hauswirth, Co-Founder & Member of Ophthalmology Scientific Advisory Board
  • Dr. Richard Jude Samulski Ph.D., Co-Founder
  • Dr. Terence R. Flotte M.D., Co-Founder
  • Mr. Jonathan I. Lieber M.B.A., Chief Financial Officer (Age 52)
  • Mr. Gerald Anthony Reynolds, Chief Accounting Officer, Principal Accounting Officer & Treasurer
  • Dr. Abraham Scaria Ph.D., Chief Scientific Officer
What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.62%), Assenagon Asset Management S.A. (0.65%), Group One Trading L.P. (0.00%), Dimensional Fund Advisors LP (0.47%), CI Investments Inc. (0.38%) and State Street Corp (0.30%).
View institutional ownership trends for Applied Genetic Technologies

Which institutional investors are selling Applied Genetic Technologies stock?

AGTC stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dimensional Fund Advisors LP, State Street Corp, and Simplex Trading LLC.
View insider buying and selling activity for Applied Genetic Technologies
or view top insider-selling stocks.

Which institutional investors are buying Applied Genetic Technologies stock?

AGTC stock was acquired by a variety of institutional investors in the last quarter, including Group One Trading L.P., Vanguard Group Inc., CI Investments Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Applied Genetic Technologies
or or view top insider-buying stocks.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $0.75.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies has a market capitalization of $32.10 million and generates $500 thousand in revenue each year. The biotechnology company earns $-57.83 million in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Applied Genetic Technologies have?

Applied Genetic Technologies employs 83 workers across the globe.

What is Applied Genetic Technologies' official website?

The official website for Applied Genetic Technologies is www.agtc.com.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at (386) 462-2204 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.